Market Closed -
Other stock markets
|
Pre-market 07:47:19 am | |||
18.35 USD | +1.27% | 18.35 | 0.00% |
01:28pm | Raspberry Pi helps lift gloom over London IPO market | AN |
May. 14 | Global markets live: Apple, Sony, Vodafone, Booking, Walmart... |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.16 times its sales.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.72% | 15.83B | B- | ||
-22.89% | 12.31B | B | ||
-24.53% | 6.59B | B | ||
+15.23% | 6.45B | C | ||
-12.43% | 5.94B | C+ | ||
+0.58% | 4.66B | D- | ||
+62.00% | 4.59B | C | ||
-5.94% | 3.96B | B | ||
-9.36% | 3.55B | C- | ||
-6.71% | 3.06B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.